Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Etoposide Capsules Generic Name & Formulations
Legal Class
Rx
General Description
Etoposide 50mg; contain parabens.
Pharmacological Class
Topoisomerase inhibitor.
How Supplied
Contact supplier.
Manufacturer
Etoposide Capsules Indications
Indications
Small cell lung cancer.
Etoposide Capsules Dosage and Administration
Adult
Round dose to nearest 50mg increment. Range: 70mg/m2 per day for 4 days to 100mg/m2 per day for 5 days. Repeat course every 3 to 4 weeks after recovery (esp myelosuppression). Renal impairment (CrCl ≤50mL/min): reduce dose (see literature). Consider dose reduction with existing myelosuppression due to previous radiation or chemotherapy.
Children
Not recommended.
Etoposide Capsules Contraindications
Not Applicable
Etoposide Capsules Boxed Warnings
Not Applicable
Etoposide Capsules Warnings/Precautions
Warnings/Precautions
Monitor blood (esp CBC/differential, platelets, hemoglobin) before each cycle and during therapy; renal function. Withhold dose if platelet count <50,000/mm3 or ANC <500/mm3. Hypoalbuminemia. Elderly. Pregnancy (Cat.D); nursing mothers: not recommended.
Etoposide Capsules Pharmacokinetics
See Literature
Etoposide Capsules Interactions
Interactions
Potentiated by cyclosporine. Additive toxicity with radiation, other cytotoxic therapies.
Etoposide Capsules Adverse Reactions
Adverse Reactions
GI upset, mucositis, myelosuppression (esp. neutropenia, thrombocytopenia; may be fatal), alopecia, fever, infections, peripheral neurotoxicity; hypersensitivity reactions, acute leukemia (rare); others.
Etoposide Capsules Clinical Trials
See Literature
Etoposide Capsules Note
Notes
Formerly known under the brand name VePesid.
Etoposide Capsules Patient Counseling
See Literature
